COVID-19 associated Mucormycosis: Prominent features, diagnoses, management, and treatment

Niusha Zare; Seyedeh Elaheh Asksri; Sara Mojtahedi; Maryam Mohammad Alizadeh Chafjiri

doi:10.53022/oarjbp.2022.5.1.0042

COVID-19 associated Mucormycosis: Prominent features, diagnoses, management, and treatment

Niusha Zare ¹, Seyedeh Elaheh Asksri ², Sara Mojtahedi ³ and Maryam Mohammad Alizadeh Chafjiri ^{4, *}

¹ Radiology Department, Dental Faculty of Tehran University of Medical Science Islamic Azad University, Tehran, Iran.

² DDS, Private Practice, Huston, Texas, USA.

³DDS, Remarkable smiles Orthodontics Irvine, CA, USA.

⁴Oral and Maxillofacial Pathology, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Review Article

Open Access Research Journal of Biology and Pharmacy, 2022, 05(01), 007–011.

Article DOI: 10.53022/oarjbp.2022.5.1.0042

DOI url: https://doi.org/10.53022/oarjbp.2022.5.1.0042

Publication history:

Received on 03 April 2022; revised on 12 May 2022; accepted on 14 May 2022

Abstract:

COVID-19-associated infections are increasing the burden on the overall health system. Mucormycosis is also related to coronavirus 2 disease and it is termed black fungus a life-threatening fungal infection caused by mucormycosis. Mucormycosis mostly affects diabetic and immunocompromised individuals. The major aim of this study is to discuss the features of COVID-19 associated mucormycosis, diagnosis, prevention, and treatment.

Keywords:

Covid-19; Mucormycosis; Diagnosis; Oral manifestation

Full text article in PDF:

Click here

COVID-19 associated Mucormycosis: Prominent features, diagnoses, management, and treatment

Niusha Zare 1, Seyedeh Elaheh Asksri 2, Sara Mojtahedi 3 and Maryam Mohammad Alizadeh Chafjiri 4, *

Niusha Zare ¹, Seyedeh Elaheh Asksri ², Sara Mojtahedi ³ and Maryam Mohammad Alizadeh Chafjiri ^{4, *}